UNSPSC 51162017: Chlorpheniramine/ephedrine/guaifenesin/phenobarbital/theophylline

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.

UNSPSC 51162017 Chlorpheniramine/ephedrine/guaifenesin/phenobarbital/theophylline is a Commodity code with limited recent state and local activity directly aligned to its nominal scope; the few posted opportunities do not match the specific pharmaceutical formulation this code identifies. Instead, state and local buyers have recently solicited naloxone and drug deactivation systems, on-site pharmacy services, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products under related UNSPSC categories. The code shows no concrete recent work being actively procured under its exact formulation classification, suggesting either narrow utilization within specific jurisdictions or administrative tagging that does not reflect current buying patterns.

The most recent opportunities with tangential relevance span Seminole County, Florida (procuring naloxone and drug deactivation systems via IFB), Hall County, Georgia (soliciting on-site pharmacy services via RFQ/P), the Texas Health and Human Services Commission (issuing an RFI for direct-to-manufacturer prescription programs), and the Minnesota Multistate Cooperative Purchasing Alliance (issuing an RFP for generic multi-source pharmaceuticals and OTC products with participation from state and local entities across multiple states including Oregon). Geographic spread includes Florida, Georgia, Texas, and Minnesota-led cooperative procurement serving multiple jurisdictions. Because the source shows no recent solicitations specifically matching the formulation named in UNSPSC 51162017, firms evaluating this code should verify whether state and local procurement offices are actively buying this particular pharmaceutical combination or whether demand is concentrated in specialized health-system or county pharmacy channels not recently advertised through open solicitation.